EW
KALV

Evoke Wealth’s KalVista Pharmaceuticals KALV Stock Holding History

Evoke Wealth’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$635K Sell
31,542
-299
-0.9% -$4.82K 0.01% 361
2025
Q4 		$514K Sell
31,841
-212
-0.7% -$2.81K 0.01% 384
2025
Q3 		$390K Sell
32,053
-128
-0.4% -$1.77K 0.01% 430
2025
Q2 		$364K Sell
32,181
-265
-0.8% -$3.24K 0.01% 409
2025
Q1 		$374K Buy
32,446
+83
+0.3% +$847 0.01% 318
2024
Q4 		$274K Hold
32,363
– – 0.01% 359
2024
Q3 		$375K Buy
32,363
+16,990
+111% +$214K 0.01% 303
2024
Q2 		$181K Buy
+15,373
New +$179K 0.21% 88
2023
Q1 		– Sell
-25,583
Closed -$173K – 365
2022
Q4 		$173K Hold
25,583
– – 0.01% 341
2022
Q3 		$371K Hold
25,583
– – 0.02% 241
2022
Q2 		$252K Hold
25,583
– – 0.01% 286
2022
Q1 		$377K Hold
25,583
– – 0.01% 261
2021
Q4 		$338K Buy
+25,583
New +$407K 0.01% 287

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Evoke Wealth's KALV Position: Q1 2026 in Review

Evoke Wealth reduced its KalVista Pharmaceuticals (KALV) stake by 0.94% in Q1 2026, selling an estimated $4.82K and leaving 31,542 shares worth $635K. The position accounts for 0.01% of the portfolio, ranked #361.

Evoke Wealth first reported a position in KALV in Q4 2021 and has held it in 13 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Evoke Wealth held 31,542 shares of KalVista Pharmaceuticals worth $635K as of Q1 2026.
  • Evoke Wealth sold 299 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.82K.
  • KalVista Pharmaceuticals made up 0.01% of Evoke Wealth's portfolio in Q1 2026, its #361 holding.
  • Evoke Wealth first reported a position in KalVista Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.